Femasys (FEMY) EBITDA Margin (2020 - 2025)
Femasys (FEMY) reported EBITDA Margin of 941.09% for Q2 2025, up 108260.0% on a YoY basis from N/an in Q2 2024, and up 41.19% quarter-over-quarter from 1600.11% in Q1 2025.
Femasys (FEMY) EBITDA Margin (2020 - 2025) Analysis & Trends
Femasys has reported EBITDA Margin for 6 years, with the latest figure at 941.09% in Q2 2025.
- For the quarter ending Q2 2025, EBITDA Margin rose 108260.0% year-over-year to 941.09%; the trailing twelve-month figure through Jun 2025 stood at 1015.0% (up 71910.0% YoY), and the FY2025 full-year result was 766.95%, up 32480.0% from the prior year.
- EBITDA Margin for Q2 2025 stood at 941.09%, up from 1600.11% in the prior quarter.
- The five-year high for EBITDA Margin was 332.22% in Q2 2021, with the low at 2087.89% in Q4 2023.
- Historically, EBITDA Margin has averaged 1104.14% across 5 years, with a median of 926.12% in 2021.
- The largest YoY upside for EBITDA Margin was 127586 bps in 2024 against a maximum downside of 110767 bps in 2024.
- Femasys' EBITDA Margin stood at 929.85% in 2021, then tumbled by 38 bps to 1280.87% in 2022, then plunged by 63 bps to 2087.89% in 2023, then surged by 61 bps to 812.03% in 2024, then decreased by 16 bps to 941.09% in 2025.
- The last three EBITDA Margin figures came in at 941.09% (Q2 2025), 1600.11% (Q1 2025), and 812.03% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 28.86% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 1.97% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 1.63% |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 34.92% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 20.96% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 4.04% |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -9.90% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 13.65% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.44% |
| 10 | Femasys | 254.59 Mn | 249.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -941.09% |
| Mar 31, 2025 | -1,600.11% |
| Dec 31, 2024 | -812.03% |
| Sep 30, 2024 | -922.39% |
| Jun 30, 2024 | -2,023.69% |
| Mar 31, 2024 | -1,277.07% |
| Dec 31, 2023 | -2,087.89% |
| Sep 30, 2023 | -1,670.18% |
| Jun 30, 2023 | -916.02% |
| Mar 31, 2023 | -1,034.64% |
| Dec 31, 2022 | -1,280.87% |
| Sep 30, 2022 | -879.88% |
| Jun 30, 2022 | -877.55% |
| Mar 31, 2022 | -896.92% |
| Dec 31, 2021 | -929.85% |
| Sep 30, 2021 | -838.23% |
| Jun 30, 2021 | -332.22% |
| Mar 31, 2021 | -553.88% |
| Dec 31, 2020 | -590.65% |
| Sep 30, 2020 | -500.72% |